Synchronous triple primary malignant tumours in the bladder, prostate, and lung harbouring TP53 and MEK1 mutations accompanied with severe cardiovascular diseases: A case report.

Autor:	Li ZK; School of Medical Imaging, North Sichuan Medical College, Nanchong, China.; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China., Zhao Q; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China., Li NF; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China., Wen J; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China., Tan BX; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China., Ma DY; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China., Du GB; Department of Oncology, The First Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South Road, Shunqing District, Nanchong 637000, Sichuan, China.
Jazyk:	angličtina
Zdroj:	Open medicine (Warsaw, Poland) [Open Med (Wars)] 2022 Dec 14; Vol. 17 (1), pp. 2046-2051. Date of Electronic Publication: 2022 Dec 14 (Print Publication: 2022).
DOI:	10.1515/med-2022-0616
Abstrakt:	Although the incidence of multiple primary malignancies (MPMs) is increasing, synchronous triple primary malignant tumours with prostate, bladder and lung is rarely reported. Gene mutation is thought to be a reason for MPMs, and severe cardiovascular diseases may interrupt the cancer treatment. Here we reported a 64-year-old male patient with synchronous triple primary malignant tumours of the bladder urothelial carcinoma, prostate adenocarcinoma, and non-small cell lung cancer (NSCLC) with mutations in TP53 and MEK1, all the three malignancies were diagnosed within 10 days. Although being interrupted by severe cardiovascular diseases (including myocardial infarction, venous thrombosis, and aneurism of the aortic root), he was successfully treated with radical cystoprostatectomy, chemotherapy plus pembrolizumab (a PD-1 antibody), and radiotherapy of the lung lesion, followed by maintenance monotherapy of pembrolizumab, overall survival was more than 26 months. In conclusion, a patient of synchronous triple primary malignant tumours with prostate, bladder, and lung harbouring TP53 and MEK1 mutations accompanied with severe cardiovascular diseases was treated successfully, which may suggest that comprehensive treatment, especially radical treatment such as operation and radiation, is very important for MPMs. Competing Interests: Conflict of interest: There are no conflict of interest. (© 2022 the author(s), published by De Gruyter.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu